Arcutis Biotherapeutics, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was ZORYVE Foam at $181.9 million, 49% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
|---|---|---|---|---|---|---|---|
| Revenue |
507
|
372
|
167
|
29
|
4
|
—
|
—
|
| ZORYVE Foam |
—
|
182
+154.3%
share 48.9%
|
72
share 43.0%
|
—
|
—
|
—
|
—
|
| ZORYVE Cream0.3 |
—
|
121
+42.2%
share 32.5%
|
85
+191.5%
share 51.1%
|
29
+691.8%
share 100.0%
|
4
share 100.0%
|
—
|
—
|
| ZORYVE Cream0.15 |
—
|
68
+588.2%
share 18.3%
|
10
share 6.0%
|
—
|
—
|
—
|
—
|
| Other Revenue |
—
|
—
|
—
|
30
share 104.2%
|
—
|
—
|
—
|
| ZORYVE Cream0.05 |
—
|
1
share 0.2%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARQT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1787306
- Former names
- Arcutis, Inc. (until Sep 9, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.